Category Archives: ALS Treatment

LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), an immunology company developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update Continue reading →

Read Time: Delivering the medication dantrolene through the nose rather than the mouth may help the medication penetrate the brain more effectively, potentially maximizing its therapeutic benefits in the treatment of neurodegenerative diseases, like Alzheimer's disease. In a first-of-its-kind study, researchers in the Perelman School of Medicine (PSOM) at the University of Pennsylvania showed that administering dantrolene through the nose increased its brain concentration and duration in a mouse model of Alzheimer's disease without causing obvious adverse side effects. Continue reading →

VIKEN, Sweden - March 13, 2020 - (Newswire.com) TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a 5 million Euro round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB and IBSOLVMIR, advancing the companys position within the treatment of acute and degenerative neurological diseases and cell transplantation Continue reading →

March 3, 2020 (LifeSiteNews) A U.S. Catholic priest is counting his blessings including the support of the communities he has shepherded the last five years following his recent diagnosis with a progressive neurodegenerative disease. The way of the cross that Jesus is inviting me to walk will not be easy, but He and His holy Mother Mary will uphold me. Continue reading →

PITTSBURGH (KDKA) Doctors are trying to make an FDA-approved drug treatment for Amyotrophic Lateral Sclerosis, or ALS, much less intense for both patients and caregivers. Continue reading →

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled 'Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors'. Allowed claims cover the method for manufacturing MSC-NTF cells (NurOwn) Continue reading →

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced its cash position at December 31, 2019, issued a business update and provided an outlook on its 2020 activities. GeNeuro continued to make significant clinical progress in 2019, said Jess Martin-Garcia, CEO of GeNeuro. The full 2-year results of our ANGEL-MS clinical trial of temelimab in multiple sclerosis, which were presented in September at the ECTRIMS 2019 congress, have confirmed the neuroprotective effect of temelimab in MS and demonstrated its potential against progression of the disease Continue reading →

Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Photo: Hearst Connecticut Media File Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Alexion to begin Phase 3 testing on drug to treat ALS Officials with Alexion Pharmaceuticals, which has a significant research and development presence in New Haven, announced the company will begin Phase 3 testing of one of its existing drugs for use in treating amyotrophic lateral sclerosis, also known as ALS or Lou Gehrigs disease. The study of the drug Ultomiris in treating ALS will begin before the end of March and take place over a 50-week period and evaluate 350 adults. Continue reading →

-- LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinsons disease -- LRRK2 inhibitor DNL151 Phase 1 demonstrated high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers and continues in an expanded Phase 1b study in patients with Parkinsons disease -- IND submitted for DNL310 (ETV:IDS) for Hunter syndrome, Denalis first clinical submission for a large molecule therapeutic enabled by its Transport Vehicle platform technology -- CTA approved for DNL343, a small molecule activator of EIF2B for ALS and other neurodegenerative diseases -- RIPK1 inhibitor DNL747 Phase 1b trials in Alzheimers and ALS fully enrolled and open label extension in ALS ongoing with data readouts on track for mid-2020 SOUTH SAN FRANCISCO, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Continue reading →

The pictures in the corridor, just across from the main ball room at Newarks Robert Treat Hotel, captured the martial arts greatness of Kevin Brown Thompson. A Newark native, Thompson mastered three disciplines weapons, forms and fighting and won world championships in each category, an achievement rarely attained. Hes in the Black Belt Hall of Fame, his name and accomplishments listed with legends Bruce Lee and Chuck Norris. Continue reading →